Business Context and Reporting Period
This Form 8-K is filed by Hancock Jaffe Laboratories, Inc. (HJLI), a Delaware corporation, on August 1, 2019, reporting events occurring on July 26, 2019. The filing discloses the execution of a new employment agreement with Marc H. Glickman, M.D., Senior Vice President and Chief Medical Officer, superseding a prior agreement from 2016.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity arrangements.
- Base Salary: $350,000 per year for Dr. Glickman.
- Existing Options Repricing: 184,500 options repriced from $10.00 to $2.00 per share.
- New Options Grant: 180,000 options at $2.00 per share, vesting quarterly over three years.
- Severance: Up to one year of base salary upon termination without Cause or resignation for Good Reason.
Material Changes
The primary material change is the repricing of Dr. Glickman's existing stock options from $10.00 to $2.00 per share, significantly reducing the exercise price. Additionally, the company granted new options at the reduced price of $2.00 per share. The filing does not report changes in financial performance compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary contingency noted is the severance obligation, which could result in a payout of up to $350,000 (one year of base salary) if Dr. Glickman is terminated without Cause or resigns for Good Reason, subject to the execution of a release of claims.
Investor Verification Checklist
- Verify the impact of the option repricing on the company's share count and potential dilution.
- Confirm the current market price of HJLI common stock relative to the new $2.00 exercise price.
- Review the full text of the New Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Check for any shareholder approval requirements related to the option repricing under the company's charter or exchange rules.